Regulation And Legal
Haleos Labs Subsidiary Clears USFDA Inspection with Zero Observations
Haleos Labs' material subsidiary Mahi Drugs received zero Form 483 observations in its USFDA inspection from September 15-18, 2026.
The inspection covered the API manufacturing facility in Anakapalli,
